<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Pediatric AML &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/pediatric-aml/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Tue, 02 Dec 2025 09:44:48 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>Pediatric AML &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Neuroleukemiosis: Imaging Insights in Pediatric AML Relapse</title>
		<link>https://bioengineer.org/neuroleukemiosis-imaging-insights-in-pediatric-aml-relapse/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 02 Dec 2025 09:44:44 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[CNS Infiltration]]></category>
		<category><![CDATA[Imaging Characteristics]]></category>
		<category><![CDATA[Leukemia Relapse]]></category>
		<category><![CDATA[Neuroleukemiosis]]></category>
		<category><![CDATA[Pediatric AML]]></category>
		<guid isPermaLink="false">https://bioengineer.org/neuroleukemiosis-imaging-insights-in-pediatric-aml-relapse/</guid>

					<description><![CDATA[In recent years, the medical world has been witnessing significant advancements in the understanding of various forms of leukemia and their complications. Amongst these complexities, neuroleukemiosis stands out as a particularly rare yet crucial manifestation of acute myeloid leukemia (AML), especially in the pediatric population. The exploration of this condition represents a critical area of [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">304344</post-id>	</item>
		<item>
		<title>Cytogenetic, Molecular Markers Predict Pediatric AML Outcomes</title>
		<link>https://bioengineer.org/cytogenetic-molecular-markers-predict-pediatric-aml-outcomes/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 17 Nov 2025 13:51:52 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[cytogenetic abnormalities]]></category>
		<category><![CDATA[Pediatric AML]]></category>
		<category><![CDATA[Prognostic biomarkers]]></category>
		<category><![CDATA[risk stratification]]></category>
		<category><![CDATA[survival outcomes]]></category>
		<guid isPermaLink="false">https://bioengineer.org/cytogenetic-molecular-markers-predict-pediatric-aml-outcomes/</guid>

					<description><![CDATA[In a landmark meta-analysis published in BMC Cancer, researchers have shed new light on the complex prognostic landscape of pediatric acute myeloid leukemia (AML), offering critical insights into the genetic and molecular underpinnings that dictate patient outcomes. This comprehensive study systematically aggregates data from nearly 1,650 children diagnosed with AML, aiming to untangle the prognostic [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">297818</post-id>	</item>
	</channel>
</rss>
